

Food and Drug Administration Advisory Committee Member
Acknowledgment of Financial Interests

Name of Advisory Committee Member: Susan Halabi, Ph.D.

Committee: Oncologic Drugs Advisory Committee Meeting (ODAC)

Meeting Date: September 19, 2017

I acknowledge that contingent upon public disclosure of the following financial interest related to the agenda item: the committee will discuss supplemental new drug application (sNDA) 021938/033 SUTENT (sunitinib malate) oral capsules, submitted by C.P. Pharmaceuticals International C.V., represented by Pfizer, Inc. (authorized U.S. agent). The proposed indication (use) for this product is for the adjuvant treatment of adult patients at high risk of recurrent renal cell carcinoma following nephrectomy.

I may be considered for participation in the advisory committee meeting described above.

<u>Type of Interest</u>	<u>Nature</u>	<u>Magnitude</u>
I. Personal/Immediate Family		
None		
II. Other Imputed Interests		
Study Statistician	American Society for Clinical Oncology (unrelated entity)	She does not receive personal remuneration or salary support. She does not have knowledge of study funding or value of products being contributed to the study.

I hereby request that FDA make this information publicly available on my behalf if the agency grants a waiver allowing me to participate in the meeting described above. I understand that without public disclosure of these interests, I will not participate in the advisory committee meeting described above.

_____/S/_____
Signature

_____/9/5/2017_____
Date